Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 6602821496
Loop profile: 1175287

Activities

Collapse all

Employment (1)

Gazi Üniversitesi: Ankara, Ankara, TR

2010-10-07 to present | Professor (Pharmaceutical Chemistry)
Employment
Source: Self-asserted source
Erden Banoglu

Education and qualifications (2)

University of Iowa: Iowa City, IA, US

1993-08-11 to 1997-08-02 | PhD (Medicinal and Natural Products Chemistry)
Education
Source: Self-asserted source
Erden Banoglu

Gazi Üniversitesi: Ankara, Ankara, TR

1985-09-15 to 1989-09-12 | BSc (Pharmacy)
Education
Source: Self-asserted source
Erden Banoglu

Works (50 of 100)

Items per page:
Page 1 of 2

Phenyl-benzyl-ureas with pyridazinone motif: Potent soluble epoxide hydrolase inhibitors with enhanced pharmacokinetics and efficacy in a paclitaxel-induced neuropathic pain model

European Journal of Medicinal Chemistry
2025-06 | Journal article
DOI: 10.1016/j.ejmech.2025.117510
Contributors: Deniz Lengerli; Arooj Bakht; Kübra Çalışkan; Philipp Dahlke; Nur Banu Bal; Paul M. Jordan; Burcu Çalışkan; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

Discovery of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study

Journal of Molecular Graphics and Modelling
2025-05 | Journal article
DOI: 10.1016/j.jmgm.2025.108962
Contributors: Abdurrahman Olğaç; Paul M. Jordan; Christian Kretzer; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

2‐Phenylbenzothiazoles featuring heteroaryl sulfonamide end‐capping substructures as developable mPGES‐1 inhibitors

Archiv der Pharmazie
2025-01 | Journal article
DOI: 10.1002/ardp.202400756
Contributors: Tansu Yalçın; Paul M. Jordan; Abdurrahman Olğaç; Philipp Dahlke; Tuğçe Gür Maz; Erden Banoglu; Oliver Werz; Burcu Çalışkan
Source: check_circle
Crossref

Novel Benzimidazole Derivatives as Potent Inhibitors of Microsomal Prostaglandin E2 Synthase 1 for the Potential Treatment of Inflammation, Pain, and Fever

Journal of Medicinal Chemistry
2024-12-12 | Journal article
DOI: 10.1021/acs.jmedchem.4c01883
Contributors: Azize Gizem Ergül; Paul M. Jordan; Philipp Dahlke; Nur Banu Bal; Abdurrahman Olğaç; Orhan Uludağ; Oliver Werz; Burcu Çalışkan; Erden Banoglu
Source: check_circle
Crossref

Data from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.c.7213719
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Data from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.c.7213719.v1
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Supplementary Information from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.25735665
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Supplementary Information from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.25735665.v1
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Supplementary Table S1 from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.25735662
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Supplementary Table S1 from Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

2024-05-02 | Preprint
DOI: 10.1158/0008-5472.25735662.v1
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

Cancer Research
2024-05-02 | Journal article
DOI: 10.1158/0008-5472.CAN-23-2812
Contributors: Mustafa Emre Gedik; Ozge Saatci; Nathaniel Oberholtzer; Meral Uner; Ozge Akbulut Caliskan; Metin Cetin; Mertkaya Aras; Kubra Ibis; Burcu Caliskan; Erden Banoglu et al.
Source: check_circle
Crossref

Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

ACS Omega
2023-08-29 | Journal article
DOI: 10.1021/acsomega.3c03682
Contributors: Abdurrahman Olğaç; İrfan Çapan; Philipp Dahlke; Paul M. Jordan; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

Data from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.c.6542676
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Data from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.c.6542676.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S1 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520559.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S1 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520559
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S2 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520556
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S2 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520556.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S3 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520553
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S3 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520553.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S4 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520550.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S4 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520550
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S5 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520547.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S5 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520547
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S6 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520544
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Figure S6 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520544.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Supplementary Data from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520541.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Supplementary Data from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520541
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Supplementary Tables from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520538
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Supplementary Tables from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

2023-04-03 | Preprint
DOI: 10.1158/1535-7163.22520538.v1
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Design, Synthesis and Evaluation of Aryl‐Tailored Oxadiazole‐thiones as New Urease Inhibitors

ChemistrySelect
2023-02-23 | Journal article
DOI: 10.1002/slct.202204449
Contributors: Tugce Gur Maz; H. Burak Caliskan; Irfan Capan; Burcu Caliskan; Berrin Özçelik; Erden Banoglu
Source: check_circle
Crossref

Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors

ACS Omega
2023-01-17 | Journal article
DOI: 10.1021/acsomega.2c06936
Contributors: Tugce Gur Maz; Beyzanur Koc; Paul M. Jordan; Kübra İbiş; Burcu Çalışkan; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

The 1,2,3-triazole ‘all-in-one’ ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool

Expert Opinion on Drug Discovery
2022-11-02 | Journal article
DOI: 10.1080/17460441.2022.2129613
Contributors: Deniz Lengerli; Kübra Ibis; Yahya Nural; Erden Banoglu
Source: check_circle
Crossref

Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition

ACS Omega
2022-10-18 | Journal article
DOI: 10.1021/acsomega.2c04039
Contributors: Sümeyye Turanlı; Azize Gizem Ergül; Paul M. Jordan; Abdurrahman Olğaç; Burcu Çalışkan; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity

ACS Omega
2022-10-18 | Journal article
DOI: 10.1021/acsomega.2c03405
Contributors: Sümeyye Turanlı; Esra Nalbat; Deniz Lengerli; Kübra İbiş; Sezen Güntekin Ergün; Ece Akhan Güzelcan; Mesut Muyan; Rengul Cetin-Atalay; Burcu Çalışkan; Erden Banoglu
Source: check_circle
Crossref

Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors

Archiv der Pharmazie
2022-08 | Journal article
DOI: 10.1002/ardp.202200082
Contributors: Tugce Gur Maz; Sumeyye Turanlı; H. Burak Caliskan; Burcu Çalışkan; Erden Banoglu
Source: check_circle
Crossref

Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors

ChemMedChem
2022-06-20 | Journal article
DOI: 10.1002/cmdc.202200137
Contributors: İrfan Çapan; Paul M. Jordan; Abdurrahman Olğaç; Burcu Çalışkan; Christian Kretzer; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

A Series of Thiadiazolyl‐Benzenesulfonamides Incorporating an Aromatic Tail as Isoform‐Selective, Potent Carbonic Anhydrase II/XII Inhibitors

ChemMedChem
2022-05-18 | Journal article
DOI: 10.1002/cmdc.202200056
Contributors: Erden Banoglu; Taner Ercanlı; Tuğçe Gür Maz; Daniela Vullo; Alessandro Bonardi; Paola Gratteri; Claudiu T. Supuran
Source: check_circle
Crossref

Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase

European Journal of Medicinal Chemistry
2022-03 | Journal article
DOI: 10.1016/j.ejmech.2022.114167
Contributors: Azize Gizem Ergül; Tuğçe Gür Maz; Christian Kretzer; Abdurrahman Olğaç; Paul M. Jordan; Burcu Çalışkan; Oliver Werz; Erden Banoglu
Source: check_circle
Crossref

Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201

Journal of Inflammation Research
2022-02 | Journal article
DOI: 10.2147/JIR.S345510
Contributors: Christian Kretzer; Paul M Jordan; Rossella Bilancia; Antonietta Rossi; Tuğçe Gür Maz; Erden Banoglu; Ulrich S Schubert; Oliver Werz
Source: check_circle
Crossref

1-(4-klorofenil)-3-metil-5-{4-[(2-metilfenil)metoksi]fenil}-1H-pirazol’ün Kristal Yapısı ve Hirshfeld Yüzey Analizi

Düzce Üniversitesi Bilim ve Teknoloji Dergisi
2022-01-31 | Journal article
DOI: 10.29130/dubited.823399
Contributors: Abdullah AYDIN; Sumeyye TURANLI; Mehmet AKKURT; Erden BANOĞLU; Nefise ÖZÇELİK
Source: check_circle
Crossref

Wood's lamp examination of hair and nails related to COVID‐19 treatment

Dermatologic Therapy
2021-11 | Journal article
DOI: 10.1111/dth.15174
Contributors: Betul Demir; Demet Cicek; Sedatcan Turkoglu; Neslihan Yuksel Bozdemir; Furkan Sarikurt; Erden Banoglu
Source: check_circle
Crossref

Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

European Journal of Medicinal Chemistry
2021-10 | Journal article
DOI: 10.1016/j.ejmech.2021.113489
Contributors: Kübra İbiş; Esra Nalbat; Burcu Çalışkan; Deniz Cansen Kahraman; Rengul Cetin-Atalay; Erden Banoglu
Source: check_circle
Crossref

A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

Molecular Cancer Therapeutics
2020-06-01 | Journal article
DOI: 10.1158/1535-7163.MCT-19-0957
Contributors: Ozge Akbulut; Deniz Lengerli; Ozge Saatci; Elif Duman; Urartu O.S. Seker; Aynur Isik; Aytekin Akyol; Burcu Caliskan; Erden Banoglu; Ozgur Sahin
Source: check_circle
Crossref

Discovery of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol

Journal of Chemical Information and Modeling
2020-03-23 | Journal article
DOI: 10.1021/acs.jcim.9b00941
Contributors: Abdurrahman Olgac; Andrea Carotti; Christian Kretzer; Stephanie Zergiebel; Andreas Seeling; Ulrike Garscha; Oliver Werz; Antonio Macchiarulo; Erden Banoglu
Source: check_circle
Crossref

Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors

European Journal of Medicinal Chemistry
2019-10 | Journal article
DOI: 10.1016/j.ejmech.2019.07.033
Contributors: Mariarosaria Boccellino; Maria Donniacuo; Ferdinando Bruno; Barbara Rinaldi; Lucio Quagliuolo; Marika Ambruosi; Simona Pace; Mario De Rosa; Abdurrahman Olgaç; Erden Banoglu et al.
Source: check_circle
Crossref

Crystal structure and Hirshfeld surface analysis of 1-(2,4-dichlorobenzyl)-5-methyl- N -(thiophene-2-sulfonyl)-1 H -pyrazole-3-carboxamide

Acta Crystallographica Section E: Crystallographic Communications
2018 | Journal article
DOI: 10.1107/S2056989018006242
EID:

2-s2.0-85046765165
Contributors: Aydin, A.; Akkurt, M.; Gur, Z.T.; Banoǧlu, E.
Source: Self-asserted source
Erden Banoglu via Scopus - Elsevier

Novel piperazine amides of cinnamic acid derivatives as tyrosinase inhibitors

Letters in Drug Design and Discovery
2018 | Journal article
DOI: 10.2174/1570180815666180420105652
EID:

2-s2.0-85059272082
Contributors: Gür, Z.T.; Şenol, F.S.; Shekfeh, S.; Orhan, İ.E.; Banoğlu, E.; Çalişkan, B.
Source: Self-asserted source
Erden Banoglu via Scopus - Elsevier

Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation

European Journal of Medicinal Chemistry
2018 | Journal article
DOI: 10.1016/j.ejmech.2018.05.041
EID:

2-s2.0-85049799768
Contributors: Bruno, F.; Errico, S.; Pace, S.; Nawrozkij, M.B.; Mkrtchyan, A.S.; Guida, F.; Maisto, R.; Olgaç, A.; D'Amico, M.; Maione, S. et al.
Source: Self-asserted source
Erden Banoglu via Scopus - Elsevier

Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents

Journal of Enzyme Inhibition and Medicinal Chemistry
2018 | Journal article
DOI: 10.1080/14756366.2018.1504041
EID:

2-s2.0-85054078743
Contributors: Çalışkan, B.; Sinoplu, E.; İbiş, K.; Akhan Güzelcan, E.; Çetin Atalay, R.; Banoglu, E.
Source: Self-asserted source
Erden Banoglu via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (82 reviews for 23 publications/grants)

Review activity for ACS medicinal chemistry letters. (6)
Review activity for Archiv der Pharmazie. (3)
Review activity for Archives of pharmacal research. (1)
Review activity for Biochimica and biophysica acta. (1)
Review activity for Biochimica et biophysica acta. (1)
Review activity for Biomedical research. (1)
Review activity for Bioorganic & medicinal chemistry. (4)
Review activity for Bioorganic chemistry. (5)
Review activity for Bioorganic chemistry. (2)
Review activity for Chemical biology & drug design. (3)
Review activity for ChemistrySelect (5)
Review activity for Current bioactive compounds. (1)
Review activity for European journal of medicinal chemistry. (8)
Review activity for European journal of medicinal chemistry. (15)
Review activity for Expert opinion on drug discovery (1)
Review activity for Frontiers in pharmacology. (1)
Review activity for Future medicinal chemistry. (2)
Review activity for Journal of agricultural and food chemistry. (1)
Review activity for Journal of enzyme inhibition and medicinal chemistry. (12)
Review activity for Journal of medicinal chemistry. (6)
Review activity for Journal of molecular structure. (1)
Review activity for Mini-reviews in medicinal chemistry. (1)
Review activity for Nature communications (1)
How many people are using ORCID?